Home Cart Sign in  
Chemical Structure| 96187-53-0 Chemical Structure| 96187-53-0

Structure of Brequinar
CAS No.: 96187-53-0

Chemical Structure| 96187-53-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Brequinar (DUP785) is a potent inhibitor of dihydroorotate dehydrogenase (DHODH) with an IC50 of 5.2 nM for human DHODH. Brequinar has potent activities against a broad spectrum of viruses.

Synonyms: DUP785; NSC 368390

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

da Silva Emery, Flavio ; Vaidergorn, Miguel M ; Purificação, Aline D ; Leite, Pedro IP ; Silva-Mendonça, Sabrina ; Silva, Wemenes JL , et al.

Abstract: In response to the rising challenge of pathogen resistance to anti-infective therapies, innovative approaches such as host-directed therapy are being investigated to bypass these resistance mechanisms. Dihydroorotate dehydrogenase (DHODH) is a crucial enzyme for synthesizing pyrimidines, which are essential for RNA and DNA biosynthesis. Inhibiting DHODH can deplete the nucleotide pool, thereby impairing the replication of pathogens that depend on this pathway. In this study, we evaluated a library of fragment-like compounds against human DHODH (HsDHODH) and identified a 1,2-diarylethine scaffold as a potential new inhibitor. Utilizing the predicted binding mode and the activity of fragments 3a and 3l against HsDHODH, we designed and synthesized 14 novel diarylethine derivatives focused on improving their potency against the enzyme. The activity of the most potent compound (3e, IC50 1.50 ± 0.02µM) was translated to antiviral activity against SARS-CoV-2 in infected Calu-3 cells (EC50 1.7 ± 0.5µM), with low cytotoxicity. Early ADME in vitro evaluation indicated a need for improved solubility, which will be addressed in subsequent multi-parameter optimization efforts. These findings pave the way for developing novel HsDHODH inhibitors with enhanced pharmacological and pharmacokinetics profiles, offering a promising strategy to address viral diseases that are resistant to conventional treatments.

Keywords: Dihydroorotate dehydrogenase ; fragments ; antiviral ; host-directed therapy ; diarylethines

Purchased from AmBeed:

Alternative Products

Product Details of Brequinar

CAS No. :96187-53-0
Formula : C23H15F2NO2
M.W : 375.37
SMILES Code : O=C(C1=C(C)C(C2=CC=C(C3=CC=CC=C3F)C=C2)=NC4=CC=C(F)C=C14)O
Synonyms :
DUP785; NSC 368390
MDL No. :MFCD00866437
InChI Key :PHEZJEYUWHETKO-UHFFFAOYSA-N
Pubchem ID :57030

Safety of Brequinar

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
4T1 cells 100 μg/mL 24 hours To evaluate the antitumor effect of Brequinar in 4T1 cells, the results showed a significant reduction in cell survival rate. PMC11626936
Lys-GFP-ER-HoxA9 cells 10 μM 48 hours Inhibition of DHODH activity, leading to the accumulation of the upstream metabolite DHO and the depletion of downstream metabolites such as UMP, uridine, UDP, UDP-GlcNAc, and UDP-glucose PMC7360335
THP1 cells 1 μM BRQ triggers differentiation of THP1 cells in vitro PMC7360335
Mouse bone marrow cells 1 μM 96 hours Brequinar inhibited the iμMune-suppressive activity of MDSCs and promoted myeloid cell maturation, particularly affecting the PMN-MDSC subset. PMC9711879
Human bone marrow cells 1 μM 96 hours Brequinar promoted myeloid maturation and inhibited the expression of an iμMune-suppressive phenotype in human myeloid cells. PMC9711879
IMSCs 100 nM 7 days Evaluate the effect of BRQ on iMSCs survival, results showed iMSCs were highly tolerant to BRQ PMC9939518
HiPSCs (1231A3) 50 nM 7 days Evaluate the effect of BRQ on hiPSCs survival, results showed 50 nM BRQ completely eradicated hiPSCs PMC9939518

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice 4T1 tumor model intravenous injection 60 mg/kg Once daily for 7 days To evaluate the antitumor effect of Brequinar in the 4T1 tumor model, the results showed significant inhibition of tumor growth and a 100% survival rate in mice. PMC11626936
mice THP1 subcutaneous xenograft model intraperitoneal injection 30 mg/kg every three days until the endpoint BRQ slowed THP1 tumor growth and induced differentiation of THP1 cells PMC7360335
Mouse 4T1 and E0771.ML-1 mammary tumor models Intraperitoneal injection 5.0 mg/kg Single injection, observed for 35 days Brequinar enhanced the antitumor activity of anti-PD-1 therapy and reduced spontaneous lung metastases. PMC9711879

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.66mL

0.53mL

0.27mL

13.32mL

2.66mL

1.33mL

26.64mL

5.33mL

2.66mL

References

 

Historical Records

Categories